-

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to Explore iPSC and Cardiomyocyte Business Opportunities

TOKYO--(BUSINESS WIRE)--Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has entered into agreement with ITOCHU CHEMICAL FRONTIER Corporation (headquartered in Minato-ku, Tokyo; President & CEO Tsutomu Miyazaki, hereinafter ICF) to form a financial business partnership. In accordance with the partnership, ICF will invest in Heartseed in an extension round of its Series B financing.

ICF is a fully owned subsidiary of ITOCHU Corporation, one of the largest general trading companies, and plays a key role in fine and specialty organic chemicals in the group.

Through this partnership, Heartseed will leverage ICF’s global network of academia and research institutions to explore iPS-Cell and Cardiomyocyte-related business opportunities.

Heartseed previously announced it raised 2.8 billion yen (approx. US$26 million) in the Series B in November 2019 from SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Venture Capital, and Astellas Venture Management LLC.

Heartseed expects to initiate Phase 1/2 clinical trial for its lead pipeline HS-001 for HF with reduced Ejection Fraction (HFrEF) in late 2020. Heartseed is also supporting an investigator-initiated clinical trial for Dilated Cardiomyopathy led by Keio University. Keio University expert panel approved its clinical trial plan in February 2020.

About Heartseed

Heartseed Inc. was founded in 2015 to develop and commercialize cardiac regenerative medicine developed by Prof. Keiichi Fukuda and his group at the Department of Cardiology, Keio University, Tokyo. Heartseed has original technologies throughout the process of manufacturing and delivering iPSC-derived cardiac regenerative medicine, including purification, cell delivery and iPSC production.

Company Name:

Heartseed Inc.

Established:

November 30, 2015

President :

Keiichi Fukuda

Headquarter:

Art Complex Center 302, Daikyocho 12-9, Shinjuku-ku, Tokyo, Japan

Shareholders:

 

Founders/Employees/Angel Bridge/Astellas Venture Management/Shibuya Corporation/
SBI Investment, JMDC, Gene Techno Science, Nissay Capital, SMBC Venture Capital

Website:

http://www.heartseed.jp/en/index.html

For more information on Heartseed, please visit http://www.heartseed.jp/en/index.html

Contacts

Kikuo Yasui,
COO, Heartseed Inc.
Tel: +81-3-6380-1068
Email: kikuo.yasui@heartseed.jp

Industry:

Heartseed Inc.

Release Summary
Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to Explore iPSC and Cardiomyocyte Business Opportunities
Release Versions
English
Hashtags
#biotech
#bioventure
#cardiomyocyte
#celltherapy
#fundraising
#heartfailure
#iPS
#regenerativemedicine
#stemcell

Contacts

Kikuo Yasui,
COO, Heartseed Inc.
Tel: +81-3-6380-1068
Email: kikuo.yasui@heartseed.jp

Social Media Profiles
HEARTSEED on LinkedIn
More News From Heartseed Inc.

Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

TOKYO & PALO ALTO, Calif.--(BUSINESS WIRE)--Heartseed Inc. ("Heartseed"), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc. ("I Peace"), a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multiple donor-derived iPS cell lines produced by I Peace and Heartseed's proprietary cardiomyocytes differentiation and purification methods. As a result, Heartseed has successfully produced high-puri...

Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology

TOKYO--(BUSINESS WIRE)--Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two patients in the Phase 1/2 clinical trial (LAPiS Study) of HS-001 in combination with coronary artery bypass grafting surgery for advanced heart failure, was presented by the investigator at the 71st Annual Meeting of the Japanese College of Cardiology (JCC) on September 9, 2023. Dr. Yuki Ichihara, Departmen...

Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy

TOKYO--(BUSINESS WIRE)--Heartseed Inc. (CEO: Keiichi Fukuda) today announced that it has entered into a worldwide non-exclusive patent license agreement (“Agreement”) with an undisclosed biotech company (“Licensee”) for its Metabolic Selection technology, a proprietary platform used to selectively remove undifferentiated induced pluripotent stem cells (iPSCs). This technology addresses the need to eliminate potentially tumor-causing undifferentiated iPSCs as the clinical use of iPSC-based cell...
Back to Newsroom